Advancing EPA-Based Therapeutics for Cardiovascular Risk Reduction
A biotech spin-off advancing a best-in-class EPA prodrug platform to address residual cardiovascular risk in statin-treated patients.
Spin-off from Universidad Autónoma de Madrid (UAM) and 4Ammonium Biotech.
Residual Cardiovascular Risk Remains a Major Unmet Need
Cardiovascular disease affects over 500 million people globally and causes approximately 18 million deaths annually. Statins reduce risk, but a substantial proportion of patients remain exposed to residual cardiovascular risk despite optimized lipid-lowering therapy.
- Statins reduce major events ~25%
- Significant residual risk remains
- Need for more efficient EPA delivery
Differentiation at the Molecular and IP Level
Drug discovery and lipid chemistry expertise.
Experienced Scientific and Execution Leadership
The founding team combines academic expertise in lipid science and medicinal chemistry with experience in drug discovery, biotech venture building, and business development.
Venture building, partnerships, and financing experience.